Procyon Advisors LLC Acquires 32,590 Shares of Haleon plc (NYSE:HLN)

Procyon Advisors LLC boosted its position in Haleon plc (NYSE:HLN - Free Report) by 14.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 262,830 shares of the company's stock after acquiring an additional 32,590 shares during the period. Procyon Advisors LLC's holdings in Haleon were worth $2,705,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of Haleon by 3.7% in the fourth quarter. FMR LLC now owns 108,827,814 shares of the company's stock valued at $1,038,217,000 after purchasing an additional 3,909,545 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Haleon by 67.5% during the fourth quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company's stock worth $146,232,000 after purchasing an additional 6,175,835 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in Haleon by 0.8% during the fourth quarter. Envestnet Asset Management Inc. now owns 7,630,307 shares of the company's stock worth $72,793,000 after purchasing an additional 58,444 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Haleon by 18.3% during the fourth quarter. JPMorgan Chase & Co. now owns 6,014,903 shares of the company's stock worth $57,382,000 after acquiring an additional 930,701 shares during the period. Finally, Northern Trust Corp lifted its holdings in Haleon by 27.7% during the fourth quarter. Northern Trust Corp now owns 5,412,542 shares of the company's stock worth $51,636,000 after acquiring an additional 1,172,931 shares during the period. Institutional investors own 6.67% of the company's stock.

Haleon Stock Performance

NYSE:HLN traded down $0.01 during trading hours on Tuesday, reaching $10.88. The stock had a trading volume of 11,035,786 shares, compared to its average volume of 8,808,321. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock has a 50 day simple moving average of $10.52 and a 200 day simple moving average of $10.05. Haleon plc has a 12-month low of $8.25 and a 12-month high of $11.42. The stock has a market cap of $48.97 billion, a P/E ratio of 31.99, a price-to-earnings-growth ratio of 2.82 and a beta of 0.31.

Wall Street Analysts Forecast Growth

HLN has been the topic of a number of recent analyst reports. Barclays reiterated an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. Hsbc Global Res lowered Haleon from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. BNP Paribas upgraded Haleon to a "strong-buy" rating in a report on Tuesday, May 27th. HSBC reiterated a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Finally, BNP Paribas Exane upgraded Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price target on the stock in a report on Tuesday, May 27th. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $12.33.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.